Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Jan 24, 2007 2:15pm
268 Views
Post# 12082292

RE: Judge's ruling on HML for Catalyst

RE: Judge's ruling on HML for CatalystI personally am not sure how this might even remotely be negative for PLI short term... I think this is absolutely the best possible scenario outcome. WE have a REAL company interested and capable in creating a REAL business plan with Prometic. A company that can be a cornerstone of Prometic's recurring income and value for years to come and showcase the technology to the world. The market WILL begin to see this picture of the future more clearly over coming months and we will continue adding significant institutional investor support. ( which has been grossly lacking ) We are squarely on the road to credibility for the first time in 3 years.... uncertainty is being replaced by certainty. I am not suggesting that there wont be some volatility and continued turnover of the investor base.... but I would be very surprised if we arent substantially higher 3 months, six months and a year from now... Think about what's likely to happen in the next six months as this Catalyst / Hemosol thing is resolved... and a new JV or business plan becomes evident... WE launch Maco PRDT filters and get significant orders from Governmental National Blood agencies... We will get some clarity and results from 1402 clinical trials... and finally our large Gel recurring order base will be bigger than ever as we roll out these larger programs with Glaxo, Novo, Nabi and others.... this is all real...and I dont think the current share price even remotely expresses this eventuality
Bullboard Posts